Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

Next Previous
X
Search
Trial Profile

A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belantamab mafodotin (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Therapeutic Use
  • Acronyms EMN27

    • Most Recent Events

    • 12 Dec 2023 Results (n=28; data cutoff date: 31 May 2023) of an analysis assessing efficacy and safety of belamaf monotherapy in RRAL amyloidosis patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (n=27) assessing belantamab mafodotin monotherapy for the treatment of patients with relapsed refractory AL amyloidosis including those traditionally excluded from clinical trials (eGFR<30 ml/min/1.73m2 and cardiac Mayo stage IIIb disease), presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 15 Jun 2023 Interim results (n=25) assessing efficacy and safety of belamafmonotherapy in pts with RRAL amyloidosis presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top